News & Updates
Filter by Specialty:
Pyrotinib plus trastuzumab-docetaxel prolongs PFS in breast cancer
Treatment with pyrotinib in combination with trastuzumab and docetaxel (tras/doc) results in longer progression-free survival (PFS) than placebo combined with tras/doc in patients with untreated HER2-positive metastatic breast cancer, a study has shown. In addition, the safely profile of tras/doc plus pyrotinib is manageable.
Pyrotinib plus trastuzumab-docetaxel prolongs PFS in breast cancer
10 Nov 2023
LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.
LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
08 Nov 2023
Neoadjuvant immunotherapy delivers better response in NSCLC
Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.
Neoadjuvant immunotherapy delivers better response in NSCLC
08 Nov 2023
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).
Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer
08 Nov 2023
Placebo effect delivers in open-angle glaucoma
Treatment with placebo is successful in patients with open-angle glaucoma or ocular hypertension, achieving lower intraocular pressure (IOP), compared with untreated control participants, reports a recent study.
Placebo effect delivers in open-angle glaucoma
07 Nov 2023
Nirmatrelvir-ritonavir benefits persist against COVID
Management of most adults with COVID-19, particularly those with mild-to-moderate disease, is increasingly occurring in the outpatient setting due to the availability of effective treatment options.